Endocrinology, Vol 112, 1567-1577, Copyright © 1983 by Endocrine Society

ARTICLES

Dopamine receptors on intact anterior pituitary cells in culture: functional association with the inhibition of prolactin and thyrotropin

SM Foord, JR Peters, C Dieguez, MF Scanlon and R Hall

Dopamine (DA) and the dopaminergic agonists bromocriptine and apomorphine inhibit the secretion of TSH as well as that of PRL by rat anterior pituitary (AP) cells in monolayer culture. The order of potency of the drugs is the same for the inhibition of both hormones: bromocriptine ED50 = 0.006 nM against PRL and 0.017 nM against TSH; apomorphine ED50 = 2.9 and 4.8 nM, respectively, and DA, ED50 = 30 and 370 nM, respectively. The dopaminergic antagonists domperidone (DOM) and metoclopramide prevent the inhibition of TSH and PRL by 10(-6) M DA (IC50 = 0.012 and 0.32 nM for metoclopramide against PRL and TSH, respectively; similarly, IC50 = 0.01 and 0.61 nM for DOM). The action of butaclamol is shown to be stereospecific, in that the (+) isomer is 1000-fold more potent in reversing the inhibition of both TSH and PRL by 10(-6) M DA than the (-) isomer [IC50 = 1.1 and 7200 nM for the (+) and (-) isomers against PRL; similarly, 6.3 and 2600 nM against TSH]. The use of radioligand-binding techniques with tritiated DOM ([3H]DOM) and dihydroergocriptine ([3H]DHE) has demonstrated a high affinity dopaminergic binding site upon rat AP cells under the same conditions as the cell cultures used in the hormone secretion studies. Both ligands have been shown to label a site with high affinity (Kd = 1-2 nM) and low capacity (2-3 fmol/10(5) cells). At this site, dopaminergic agonists and antagonists compete with both radioligands and display a rank order of potency which is the same as that shown against TSH and PRL secretion and which is typically dopaminergic. For [3H]DHE: bromocriptine Ki (0.04 nM) greater than metoclopramide = DOM (0.07 nM) greater than (+)butaclamol (0.7 nM) greater than apomorphine (20 nM) greater than DA (700 nM) greater than (-)butaclamol (2000 nM). Similar data were derived using [3H]DOM. The high affinity site is saturable, has rapid association and dissociation rates, as determined for both radioligands used, and is temperature dependent. In contrast, both radioligands bind to a second binding site on the cells that is of lower affinity (Kd = 244 nM for [3H]DOM and 678 nM for [3H]DHE) and larger capacity (100 fmol/10(5) cells for both ligands). This second site is neither stereospecific nor, using the methodology presented here, does it discriminate between other dopaminergic compounds. It is thus not considered to represent specific DA receptor binding. It is concluded that the dopaminergic stimulus causing the inhibition of TSH and PRL secretion from rat AP cells in culture is mediated via a high affinity DA receptor present upon lactotrophs and thyrotrophs and that this receptor has similar characteristics on the two cell types.

This article has been cited by other articles:

				R. Pivonello, D. Ferone, G. Lombardi, A. Colao, S. W J Lamberts, and L. J Hofland Novel insights in dopamine receptor physiology Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S13 - S21. [Abstract] [Full Text] [PDF]

				F.-A. Weltzien, C. Pasqualini, M.-E. Sebert, B. Vidal, N. Le Belle, O. Kah, P. Vernier, and S. Dufour Androgen-Dependent Stimulation of Brain Dopaminergic Systems in the Female European Eel (Anguilla anguilla) Endocrinology, June 1, 2006; 147(6): 2964 - 2973. [Abstract] [Full Text] [PDF]

				M J Tansey and J A Schlechte Pituitary production of prolactin and prolactin-suppressing drugs Lupus, October 1, 2001; 10(10): 660 - 664. [Abstract] [PDF]

				M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy Prolactin: Structure, Function, and Regulation of Secretion Physiol Rev, October 1, 2000; 80(4): 1523 - 1631. [Abstract] [Full Text] [PDF]

				F. R. Perez, X. Casabiell, J. P. Camina, J. L. Zugaza, and F. F. Casanueva cis-Unsaturated Free Fatty Acids Block Growth Hormone and Prolactin Secretion in Thyrotropin-Releasing Hormone-Stimulated GH3 Cells by Perturbing the Function of Plasma Membrane Integral Proteins Endocrinology, January 1, 1997; 138(1): 264 - 272. [Abstract] [Full Text] [PDF]